Endocyte Inc., of West Lafayette, Ind., presented poster updates on its two lead clinical programs and said EC1456 and EC1169 have shown anti-tumor activity during the dose escalation phase of their respective trials, even in patients not specifically identified as positive for the drug targets. The activity seen to date with EC1169 in prostate cancer patients is particularly encouraging, the firm said, with the first confirmed radiologic partial response recorded.